Report cover image

Global Acinetobacter Infections Treatment Supply, Demand and Key Producers, 2026-2032

Publisher GlobalInfoResearch
Published Jan 05, 2026
Length 113 Pages
SKU # GFSH20813378

Description

The global Acinetobacter Infections Treatment market size is expected to reach $ million by 2032, rising at a market growth of %CAGR during the forecast period (2026-2032).

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.

This report studies the global Acinetobacter Infections Treatment demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Acinetobacter Infections Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Acinetobacter Infections Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Acinetobacter Infections Treatment total market, 2021-2032, (USD Million)

Global Acinetobacter Infections Treatment total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Acinetobacter Infections Treatment total market, key domestic companies, and share, (USD Million)

Global Acinetobacter Infections Treatment revenue by player, revenue and market share 2021-2026, (USD Million)

Global Acinetobacter Infections Treatment total market by Type, CAGR, 2021-2032, (USD Million)

Global Acinetobacter Infections Treatment total market by Pipeline, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Acinetobacter Infections Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Acinetobacter Infections Treatment market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Pipeline. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Acinetobacter Infections Treatment Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Acinetobacter Infections Treatment Market, Segmentation by Type:
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others

Global Acinetobacter Infections Treatment Market, Segmentation by Pipeline:
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others

Companies Profiled:
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals

Key Questions Answered

1. How big is the global Acinetobacter Infections Treatment market?

2. What is the demand of the global Acinetobacter Infections Treatment market?

3. What is the year over year growth of the global Acinetobacter Infections Treatment market?

4. What is the total value of the global Acinetobacter Infections Treatment market?

5. Who are the Major Players in the global Acinetobacter Infections Treatment market?

6. What are the growth factors driving the market demand?

Table of Contents

113 Pages
1 Supply Summary
2 Demand Summary
3 World Acinetobacter Infections Treatment Companies Competitive Analysis
4 United States VS China VS Rest of World (by Headquarter Location)
5 Market Analysis by Type
6 Market Analysis by Pipeline
7 Company Profiles
8 Industry Chain Analysis
9 Research Findings and Conclusion
10 Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us